Janus Kinase Inhibitors and Coronavirus Disease (COVID)-19: Rationale, Clinical Evidence and Safety Issues.
TLDR
In this paper, a review of the development and use of JAK inhibitors in COVID-19, from artificial intelligence to current clinical evidence, including real world experience, and critically appraise emerging safety issues, namely infections, thrombosis, and liver injury.Citations
More filters
Journal ArticleDOI
Molecular pathways involved in COVID-19 and potential pathway-based therapeutic targets.
Masoumeh Farahani,Zahra Niknam,Leila Mohammadi Amirabad,Nasrin Amiri-Dashatan,Mehdi Koushki,Mohadeseh Nemati,Fahima Danesh Pouya,Mostafa Rezaei-Tavirani,Yousef Rasmi,Lobat Tayebi +9 more
TL;DR: In this article, a review of the possible mechanisms of the host response following SARS-CoV-2 infection and surveyed current research conducted by in-vitro, in vivo and human observations, as well as existing suggestions.
Journal ArticleDOI
Molecular pathways involved in COVID-19 and potential pathway-based therapeutic targets
TL;DR: In this paper , a review of the possible mechanisms of the host response following SARS-CoV-2 infection and surveyed current research conducted by in vitro, in vivo and human observations, as well as existing suggestions.
Journal ArticleDOI
Impact of COVID-19 on the liver and on the care of patients with chronic liver disease, hepatobiliary cancer, and liver transplantation: An updated EASL position paper
Thomas Marjot,Christiane S. Eberhardt,Tobias Boettler,Luca S. Belli,Marina Berenguer,Maria Buti,Rajiv Jalan,Mario U. Mondelli,Richard Moreau,Daniel Shouval,Thomas Berg,Markus Cornberg +11 more
TL;DR: The European Association for the Study of the Liver as mentioned in this paper provides a summary of the latest data on the impact of COVID-19 on the liver and issues guidance on the care of patients with chronic liver disease, hepatobiliary cancer, and previous liver transplantation.
Journal ArticleDOI
JAK inhibitors and COVID-19
TL;DR: Whether a class effect of JAKi may be emerging in COVID-19 treatment, although at the moment the convincing data are for baricitinib only is discussed, because the precise timing of treatment will be very important in future trials.
Journal ArticleDOI
JAK-STAT Pathway: A Novel Target to Tackle Viral Infections
TL;DR: In this article, the authors review the diversity of strategies that viruses have evolved to interfere with JAK-STAT signaling, stressing the relevance of this pathway as a putative antiviral target.
References
More filters
Journal ArticleDOI
The Complex Management of Atrial Fibrillation and Cancer in the COVID-19 Era: Drug Interactions, Thromboembolic Risk, and Proarrhythmia
Milo Gatti,Emanuel Raschi,Elisabetta Poluzzi,Cristian Martignani,Stefania Salvagni,Andrea Ardizzoni,Igor Diemberger +6 more
TL;DR: Clinical challenges in the management of oncological patients requiring anticoagulants for atrial fibrillation (AF) are summarized, also considering the current outbreak of the COVID-19 pandemic, since this infection can add challenges to themanagement of both conditions.
Journal ArticleDOI
Drug-drug interaction (DDI) assessments of ruxolitinib, a dual substrate of CYP3A4 and CYP2C9, using a verified physiologically based pharmacokinetic (PBPK) model to support regulatory submissions.
Kenichi Umehara,Felix Huth,Yi Jin,Hilmar Schiller,Vassilios Aslanis,Tycho Heimbach,Handan He +6 more
TL;DR: It is demonstrated that P BPK modeling can support characterizing DDI liabilities to inform the drug label and might help reduce the number of clinical DDI studies by simulations of untested scenarios, when a robust PBPK model is established.
Journal ArticleDOI
Mycobacterial Infections With Ruxolitinib: A Retrospective Pharmacovigilance Review.
TL;DR: Patients on ruxolitinib are at increased risk of developing MTB and AMI, and Clinicians should be aware of this risk and consider screening patients for latent MTB prior to initiating ruxolinib.
Journal ArticleDOI
Reporting of Thromboembolic Events with JAK Inhibitors: Analysis of the FAERS Database 2010–2019
TL;DR: In this paper, a potentially elevated risk for pulmonary thrombosis with Janus kinase inhibitors (JAKinibs) was identified, as well as an increased risk for portal vein thromboembolic events in ruxolitinib patients.
Journal ArticleDOI
Favorable COVID-19 course despite significant comorbidities in a ruxolitinib-treated patient with primary myelofibrosis.
Steffen Koschmieder,Edgar Jost,Christian Cornelissen,Tobias Müller,Maximilian Schulze-Hagen,Johannes Bickenbach,Gernot Marx,Michael Kleines,Nikolaus Marx,Tim H. Brümmendorf,Michael Dreher +10 more
TL;DR: Clinical evidence that ruxolitinib treatment is feasible and can be beneficial in patients with COVID‐19 pneumonia, preventing cytokine storm and ARDS is provided.